(Reuters) -Doctors advise most patients on GLP-1 obesity drugs such as Wegovy and Zepbound to stay on them to keep the weight ...

AbbVie’s second quarter saw a significant positive market response, driven by robust sales from its immunology and ...

Enthusiasm for its weight loss medications is intensifying, and several companies are preparing oral formulations.

Eli Lilly introduces its Mounjaro Kwikpen in India at ₹14,000 for the 2.5 mg starting dose, competing with Novo Nordisk’s Wegovy in the booming GLP-1 drug market for diabetes and weight loss.